CPDR Patient Education Program
Central to the CPDR Patient Education Program is the educational and counseling services provided to patients and their families by the Patient Educator, Jane Hudak, RN, PhD. At the Multi-disciplinary Prostate Cancer Clinic, she provides newly diagnosed prostate cancer patients and their families with invaluable information essential to understanding their disease and making an informed decision about their cancer treatment as well as emotional support to facilitate their adjustment to their cancer diagnosis.
The Patient Educator also provides extensive (4-5 hour) individual, couple or small-group preoperative counseling sessions for patients (and their families) scheduled to undergo a radical retropubic prostatectomy or robotic-assisted laparoscopic prostatectomy. These comprehensive sessions coach the patient and their families through the preoperative and postoperative phases of the surgery thereby facilitating their surgical recovery as well as emotional recovery. The counseling sessions are also another venue in which participation in research studies at CPDR is addressed. Another vital component of the Patient Education Program for prostatectomy patients is the Battle Buddy Program initiated in 2006. This program matches patients scheduled for a prostatectomy with "veteran" prostatectomy patients who volunteer to contact the new patient throughout their surgical experience to provide guidance and support as needed. CPDR has about 50 volunteer Battle Buddies. Approximately fifty percent of our prostatectomy patients each year (40-50) choose to be involved in the Battle Buddy Program.
The Patient Educator also provides individualized educational and counseling services to patients in the Prostate Cancer Recurrence Clinic. She provides the patients and their families with information about the various treatment options and resources with which to make an informed treatment decision as well as resources to help them cope with their progressing disease and the opportunities to participate in clinical research studies.
September 29, 2014
Genomic Health Announces Positive Results from Latest Clinical Validation Study of Oncotype DX® as Predictor of Near- and Long-term Outcomes in Racially Diverse Group of Prostate Cancer Patients
REDWOOD CITY, CA – Genomic Health, Inc. (Nasdaq: GHDX) today announced strongly positive results from an additional independent clinical validation study of the Oncotype DX® prostate cancer test, conducted in collaboration with the Uniformed Services University of the Health Sciences' (USU) Center for Prostate Disease Research (CPDR) supported by a multi-disciplinary team of investigators under a cooperative research and development agreement with USU. This new large study reconfirmed the biopsy-based test's Genomic Prostate Score (GPS) as a predictor of adverse pathology at surgery and, for the first time, validated GPS as a strong independent predictor of a rise in prostate-specific antigen (PSA) following surgery (biochemical recurrence).
Read Full Article.
Read Publication - European Urology
Read the NOVEMEBR 2014 Newsletter